Кардиометаболические факторы риска у душевнобольных


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Рассматриваются проблемы сердечно-сосудистого риска у пациентов с психическими заболеваниями. Пациентам с шизофренией и рекуррентными аффективными расстройствами свойственны нарушения углеводного и липидного обмена, которые могут усугубляться под влиянием терапии антипсихотическими препаратами. Терапия современными нейролептиками часто сопровождается развитием ожирения и метаболического синдрома. Риск развития этих нарушений зависит от используемого препарата и, возможно, генетических причин. Обсуждаются вопросы скрининга и мониторинга метаболических нарушений у пациентов, длительно получающих антипсихотические препараты.

Полный текст

Доступ закрыт

Об авторах

А. Панферов

Первый МГМУ им. И.М. Сеченова

Email: a_panferov@mail.ru
кандидат медицинских наук

Т. Авдеева

Первый МГМУ им. И.М. Сеченова

кандидат медицинских наук

Список литературы

  1. Данилов Д.С. Классификация антипсихотических средств и их значение для выбора терапии шизофрении (к 60-летию появления нейролептиков) // Журн. неврол. и психиат. им. С.С. Корсакова. - 2011; 10: 91-100.
  2. Allison B.D., Mentore J.L., Heo M. et al. Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis // Am. J. Psychiat. - 1999; 156 (11): 1686-96.
  3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes // Diabetes Care. - 2004; 27: 596-601.
  4. Bernstein H.G., Bogerts B., Lendeckel U. Cathepsin K and metabolic abnormalities in schizophrenia // Arterioscler. Thromb. Vasc. Biol. - 2008; 28 (12): 163.
  5. Bradford D.W., Kimm M.M., Braxton L.E. et al. Access to Medical Care Among Persons With Psychotic and Major Affective Disorders // Psychiat. Serv. -2008; 59 (8): 847-52.
  6. Brown L.C., Majumdar S.R., Newman S.C. et al. History of depression increases risk of type 2 diabetes in younger adults // Diabetes Care. - 2005; 28: 1063-7.
  7. Bushe C.J., Leonard B.E. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials // J. Clin. Psychiatry. - 2007; 68 (11): 1682-90.
  8. Canadian Diabetes Association. Position paper: antipsychotic medications and associated risks of weight gain and diabetes // Canad. J. Diabetes. - 2005; 29: 111-2.
  9. Carney C.P., Jones L., Woolson R.F. Medical Comorbidity in Women and Men with Schizophrenia. A Population-Based Controlled Study // J. Gen. Intern. Med. - 2006; 21: 1133-7.
  10. Correll C.U., Druss B.G. et al. Findings of a U.S. national cardiometabolic screening program among 10 084 psychiatric outpatients // Psychiat. Serv. - 2010; 61 (9): 892-8.
  11. De Hert M., van Winkel R., Van Eyck D. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a crosssectional study // Clin. Pract. Epidemiol. Ment. Health. - 2006; 2: 14.
  12. De Nayer A., De Hert M., Scheen A. et al. Belgian consensus on metabolic problems associated with atypical antipsychotics // Int. J. Psychiat. Clin. Practice. -2005; 9: 130-7.
  13. Ellingrod V.L., Miller D.D., Taylor S.F. et al. Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677C/T and 1298A/C Variants // Schizophr. Res. - 2008; 98 (1-3): 47-54.
  14. Engl J., Laimer M., Niederwanger A. et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells // Molecular. Psychiatry. - 2005; 10: 1089-96.
  15. Expert Group «Schizophrenia and Diabetes 2003» Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary // Br. J. Psychiatry. Suppl. - 2004; 47: 112-4.
  16. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L. et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder // Ann. Clin. Psychiatry. - 2008; 20 (3): 131-7.
  17. Goldberg R.W., Kreyenbuhl J.A., Medoff D.R. et al. Quality of diabetes care among adults with serious mental illness // Psychiatr. Serv. - 2007; 58 (4): 536-43.
  18. Holt R.I.G., Peveler R.C. Antipsychotic drugs and diabetes an application of the Austin Bradford Hill criteria // Diabetologia. - 2006; 49: 1467-76.
  19. Ko F., Tallerico T., Seeman P. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine // Synapse. -2006; 60 (2): 141-51.
  20. Kohen D. Diabetes mellitus and schizophrenia: historical perspective // Br. J. Psychiatry. - 2004; 184 (47): 64-6.
  21. Lambert T.J., Chapman L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement // Med. J. Aust. - 2004; 181: 544-8.
  22. Leucht S., Carves C., Arbter D. et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis // Lancet. -2009; 373 (9657): 31-41.
  23. Levine J., Stahl Z., Sela B.A. et al. Elevated homocysteine levels in young male patients with schizophrenia // Am. J. Psychiat. - 2002; 159 (10): 1790-2.
  24. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N. Engl. J. Med. - 2005; 353 (12): 1209-23.
  25. Mackin P., Bishop D.R., Watkinson H.M.O. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients // BMC Psychiat. - 2007, 7: 28.
  26. Marder S.R., Essock S.M., Miller A.L. et al. Physical Health Monitoring of Patients With Schizophrenia // Am. J. Psychiatry. - 2004; 161: 1334-49.
  27. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro // Eur. Neuropsychopharmacol. -2004; 14: 115-9.
  28. Melkersson K., Jansson E. The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro // Neuroendocrinol. Lett. - 2005; 26 (3): 205-8.
  29. Mezuk B., Eaton W.W., Albrecht S. et al. Depression and type 2 diabetes over the lifespan: a meta-analysis // Diabetes Care. - 2008; 31 (12): 2383-9.
  30. Nasrallah H.A., Meyer J.M., Goff D.C. et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline // Schizophr. Res. - 2006; 86: 15-22.
  31. Oriot P., Feys J.-L., Mertens de Wilmars S. et al. Insulin sensitivity, adjusted ß-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study // Diab. Met. - 2008; 34: 490-6.
  32. Osborn D.P., Levy G., Nazareth I. et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database // Arch. Gen. Psychiatry. - 2007; 64 (2): 242-9.
  33. Osborn D.P., Wright C.A., Levy G., King M.B. et al. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and meta-analysis // BMC Psychiat. - 2008; 8: 84.
  34. Ösby U., Correia N., Brandt L. et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study // BMJ. - 2000; 321: 483-4.
  35. Parker С., Coupland C., Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study // BMJ. - 2010; 341: 4245-54.
  36. Ray W.A., Chung C.P., Murray K.T. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death // N. Engl. J. Med. - 2009; 360 (3): 225-35.
  37. Renrong Wu, Jingping Zhao, Ping Shao et al. Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study // J. Cent. South. Univ. (Med. Sci.). - 2011; 36 (8): 720-3.
  38. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia // Am. J. Psychiat. - 2003; 160 (2): 284-9.
  39. Ryan M.C.M., Flanagan S., Kinsella U. et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia // Life Sci. - 2004; 74 (16): 1999-2008.
  40. Saha S., Chant D., McGrath J. A Systematic Review of Mortality in Schizophrenia. Is the Differential Mortality Gap Worsening Over Time? // Arch. Gen. Psychiat. - 2007; 64 (10): 1123-31.
  41. Scheen A.J., De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics // Diab. Met. - 2007; 33: 169-75.
  42. Smith M., Hopkins D., Peveler R. et al. First versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis // Br. J. Psychiat. - 2008; 192 (6): 406-11.
  43. Sowell M., Mukhopadhyay N., Cavazzoni P. et al. Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp // J. Clin. Endocrinol. Metab. - 2003; 88 (12): 5875-80.
  44. Thakore J.H., Mann J.N., Vlahos I. et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia // Int. J. Obes. - 2002; 26: 137-41.
  45. Yang M., Sun J., Liu J. et al. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism // Arterioscle. Thromb. Vasc. Biol. - 2008; 28: 2202-8.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ИД "Русский врач", 2013